MA05.071, Remote Electrical Neuromodulation for Migraines
Independence Blue Cross reissued MA05.071 with no substantive changes to Remote Electrical Neuromodulation (REN/Nerivio) coverage for migraine prevention. The policy establishes medical necessity criteria for adults (18+) and pediatric patients (8-17) with 6-24 headache days per 28-day period, requiring either failed preventive medications, pregnancy/breastfeeding status, medication overuse headache risk, or drug-drug interaction concerns. Acute migraine treatment remains non-covered (experimental/investigational). Billing teams must ensure claims comply with these eligibility criteria and HCPCS code A4540 is used for device billing.